FOLH1 and pachyonychia congenita: Similarly, both 177Lu-PSMA I&T and -PSMA 617 in PC patients showed the highest absorbed doses among healthy organs in lacrimal and parotid glands, but not enough to result in significant clinical side effects, nor interfere with their treatment (7).